Tela Bio, Inc. - TELA STOCK NEWS

TELA Bio, Inc. is set to report its first quarter financial results for the period ending March 31, 2021, on May 13, 2021. The company's management will hold a conference call and webcast at 4:30 p.m. ET to discuss these results and provide a corporate update. TELA Bio focuses on innovative tissue reinforcement materials designed for soft tissue reconstruction, aiming to offer effective biologic material repair solutions and improve clinical outcomes. The company is committed to addressing unmet needs in hernia repair, abdominal wall reconstruction, and plastic and reconstructive surgery.

TELA Bio reported fourth quarter revenue of $5.7 million, an increase of 17% year-over-year, and full-year revenue of $18.2 million, up 18% from 2019. Gross profit for Q4 was $3.7 million (65% margin), and $11.2 million (62% margin) for the full year. Operating expenses rose to $10.4 million in Q4 and $36.5 million annually, leading to net losses of $7.8 million and $28.8 million, respectively. For 2021, TELA projects revenue between $27.0 million and $30.0 million, indicating growth of 48% to 65%.

TELA Bio, a medical technology company, has reported encouraging findings from the 12-month analysis of its BRAVO study on OviTex Reinforced Tissue Matrix for ventral hernia treatment. Out of 76 patients, only two experienced a recurrence at the surgical site, while interim results at 24 months showed no recurrences among the 51 patients followed. The results demonstrate low postoperative complications, and the data have been submitted for journal publication. TELA anticipates completing the BRAVO trial this year, highlighting OviTex's potential in hernia repair.

TELA Bio, Inc. (NASDAQ: TELA), a medical technology company, will report its fourth quarter and full year 2020 financial results on March 24, 2021. The management team will host a conference call at 4:30 p.m. ET the same day to discuss these results and provide a corporate update. TELA specializes in innovative tissue reinforcement materials aimed at soft tissue reconstruction, particularly in hernia repair and abdominal wall reconstruction.

MALVERN, Pa., Feb. 4, 2021 - TELA Bio, a commercial-stage medical technology company, will participate in the BTIG Virtual MedTech Conference on February 18, 2021, at 4:30 PM EST. The company focuses on innovative tissue reinforcement materials for soft tissue reconstruction, aiming to enhance patient outcomes while minimizing reliance on synthetic materials. TELA's key products include OviTex® and OviTex PRS Reinforced Tissue Matrix, designed for hernia repair and reconstructive surgeries. Interested parties may access the webcast via their [investor relations page](https://ir.telabio.com).

TELA Bio, Inc. (Nasdaq: TELA) reported preliminary unaudited financial results for Q4 and full year 2020. Fourth quarter revenue is projected to be $5.5-5.7 million, a 13-17% increase from Q4 2019, while full-year revenue is expected to reach $18.0-18.2 million, up 17-18% from 2019. Cash and cash equivalents are anticipated at $74.4 million as of December 31, 2020. Although the COVID-19 pandemic has impacted procedural volumes and revenue growth, TELA has made progress in expanding its commercial operations and product offerings.

MALVERN, Pa., Jan. 6, 2021 – TELA Bio announces participation in the 23rd Annual Needham Virtual Growth Conference. The management is set to present on January 15, 2021, at 2:45 PM EST. Interested individuals can access the live and archived webcast at ir.telabio.com. TELA Bio focuses on developing tissue reinforcement materials for soft tissue reconstruction, aiming to address unmet medical needs.

TELA Bio, Inc. (Nasdaq: TELA) has appointed Bruce Freedman, M.D., FACS as Vice President of Clinical Development. With over 30 years in hernia repair, Dr. Freedman advocates for natural hernia mesh alternatives, specifically the OviTex Reinforced Tissue Matrix, designed to reduce foreign body responses. He will leverage his experience to promote the clinical and financial benefits of TELA's innovative products to surgeons and hospital administrators. This strategic hire aims to enhance patient access to safer hernia repair options, distinguishing TELA from larger competitors.

TELA Bio, Inc. is preparing to participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference from December 1-3, 2020. The company specializes in medical technology, developing innovative tissue reinforcement materials for soft tissue reconstruction. Their products aim to address gaps in existing biologics and reduce the long-term risks of permanent synthetic materials. Interested parties can access the fireside chat presentation link through TELA's investor relations page.